ALLIANCEBERNSTEIN L.P. - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 222 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.87 and the average weighting 0.1%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q1 2024$159,394
+23.4%
237,8300.0%0.00%
Q4 2023$129,213
-15.2%
237,830
-6.4%
0.00%
Q3 2023$152,362
-53.9%
254,0210.0%0.00%
Q2 2023$330,227
+13.0%
254,021
+53.0%
0.00%
Q1 2023$292,285
-73.6%
166,071
-52.8%
0.00%
Q4 2022$1,105,503
+48.4%
352,071
+131.5%
0.00%
Q3 2022$745,000
-59.1%
152,071
-65.4%
0.00%
-100.0%
Q2 2022$1,820,000
+105.9%
439,687
+189.1%
0.00%
Q1 2022$884,000
-22.3%
152,071
+0.2%
0.00%
Q4 2021$1,138,000
-16.8%
151,7710.0%0.00%
-100.0%
Q3 2021$1,367,000
-24.8%
151,7710.0%0.00%0.0%
Q2 2021$1,817,000
-7.3%
151,771
-3.0%
0.00%0.0%
Q1 2021$1,960,000
-17.9%
156,441
+2.2%
0.00%0.0%
Q4 2020$2,388,000
+101.7%
153,041
+22.1%
0.00%0.0%
Q3 2020$1,184,000
-9.0%
125,341
-13.7%
0.00%0.0%
Q2 2020$1,301,000
+40.6%
145,2410.0%0.00%0.0%
Q1 2020$925,000
-23.9%
145,2410.0%0.00%0.0%
Q4 2019$1,216,000
-7.5%
145,2410.0%0.00%0.0%
Q3 2019$1,314,000
-21.2%
145,241
-6.2%
0.00%0.0%
Q2 2019$1,668,000
+22.2%
154,841
+8.2%
0.00%0.0%
Q1 2019$1,365,000
-16.9%
143,0410.0%0.00%0.0%
Q4 2018$1,642,000
-32.3%
143,0410.0%0.00%
-50.0%
Q3 2018$2,425,000
+19.4%
143,0410.0%0.00%
+100.0%
Q2 2018$2,031,000
-40.5%
143,041
-20.4%
0.00%
-50.0%
Q1 2018$3,416,000
+9.3%
179,803
-5.7%
0.00%0.0%
Q4 2017$3,126,000
+9.3%
190,5830.0%0.00%0.0%
Q3 2017$2,859,000
+260.1%
190,583
+111.2%
0.00%
+100.0%
Q2 2017$794,000
+69.3%
90,2410.0%0.00%
Q1 2017$469,000
+53.3%
90,241
-10.2%
0.00%
Q4 2016$306,000
-27.7%
100,441
+10.0%
0.00%
Q3 2016$423,000
-20.0%
91,3410.0%0.00%
Q2 2016$529,000
-4.3%
91,3410.0%0.00%
Q1 2016$553,000
-40.3%
91,341
-10.0%
0.00%
-100.0%
Q4 2015$927,000
+54.2%
101,541
-4.8%
0.00%0.0%
Q3 2015$601,000
-49.2%
106,641
-0.1%
0.00%0.0%
Q2 2015$1,184,000
-21.8%
106,771
+10.6%
0.00%0.0%
Q1 2015$1,514,000
+3.1%
96,5710.0%0.00%0.0%
Q4 2014$1,469,000
+41.0%
96,5710.0%0.00%0.0%
Q3 2014$1,042,000
-29.4%
96,5710.0%0.00%0.0%
Q2 2014$1,475,000
-15.5%
96,5710.0%0.00%
-50.0%
Q1 2014$1,746,000
+46.8%
96,571
+12.9%
0.00%
+100.0%
Q4 2013$1,189,000
+32.6%
85,5710.0%0.00%0.0%
Q3 2013$897,000
+32.7%
85,571
-1.2%
0.00%0.0%
Q2 2013$676,00086,6000.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Lombard Odier Asset Management (Switzerland) SA 1,539,994$11,550,0000.74%
Golden State Equity Partners 143,768$1,078,0000.54%
Rhenman & Partners Asset Management AB 765,000$5,975,0000.40%
WASATCH ADVISORS LP 10,960,982$82,207,0000.34%
KLK CAPITAL MANAGEMENT LLC 44,323$332,0000.32%
EMC Capital Management 61,394$460,0000.25%
Rokos Capital Management LLP 539,860$4,108,0000.25%
Long Focus Capital Management, LLC 245,000$1,838,0000.24%
Vanguard Capital Wealth Advisors 33,380$250,0000.18%
Fort Sheridan Advisors LLC 74,898$562,0000.16%
View complete list of SANGAMO THERAPEUTICS INC shareholders